Granite Point Capital Management’s Matinas BioPharma MTNB Stock Holding History

Granite Point Capital Management’s Portfolio MTNB Stock Details MTNB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-30,000	Closed	-$946K	–	95
2019 Q3	$946K	Hold	30,000	–	–	0.15%	45
2019 Q2	$1.28M	Sell	30,000 -4,123	-12%	-$198K	0.09%	53
2019 Q1	$1.86M	Buy	+34,123	New	+$1.84M	0.18%	49

Other funds holding MTNB

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

RJFSA

Raymond James Financial Services Advisors St. Petersburg, Florida $75.1B AUM 31.89% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

SCA

STALEY CAPITAL ADVISERS Pittsburgh, Pennsylvania $2.36B AUM 23.72% 1-Year Est. Return

Granite Point Capital Management's MTNB Position: Q4 2019 in Review

Granite Point Capital Management sold out of Matinas BioPharma (MTNB) in Q4 2019, closing a stake of 30,000 shares — an estimated $946K sold.

Granite Point Capital Management first reported a position in MTNB in Q1 2019 and held it in 3 quarters. The position peaked at $1.86M in Q1 2019. 64 funds tracked by Wall St. Rank hold MTNB as of Q4 2019.

Granite Point Capital Management reported no remaining Matinas BioPharma position as of Q4 2019 after selling out during the quarter.
Granite Point Capital Management sold 30,000 Matinas BioPharma shares in Q4 2019, an estimated $946K.
Granite Point Capital Management first reported a position in Matinas BioPharma in Q1 2019 and held it in 3 quarters.
Granite Point Capital Management's Matinas BioPharma position peaked at $1.86M in Q1 2019.
64 funds tracked by Wall St. Rank held Matinas BioPharma as of Q4 2019.

Based on Granite Point Capital Management's 13F filing for Q4 2019, filed 10 Feb 2020.